IQVIA Selects Veeva Clinical Operations Applications
RESEARCH TRIANGLE PARK, N.C. and PLEASANTON, Calif.
PRNewsWire10/13/2026Neutral
IQV
IQVIA Holdings IncNYSEHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$44.37B
P/E Ratio
33.49
EPS
$8.05
Beta
1.17
52W High
$277.40
52W Low
$154.50
50-Day MA
$259.33
200-Day MA
$207.55
Dividend Yield
—
Profit Margin
8.10%
Forward P/E
18.42
PEG Ratio
0.97
About IQVIA Holdings Inc
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Fundamentals
| Revenue (TTM) | $16.98B |
| Gross Profit (TTM) | $5.60B |
| EBITDA | $3.05B |
| Operating Margin | 13.00% |
| Return on Equity | 22.80% |
| Return on Assets | 5.06% |
| Revenue/Share (TTM) | $100.70 |
| Book Value | $37.49 |
| Price-to-Book | 7.14 |
| Price-to-Sales (TTM) | 2.61 |
| EV/Revenue | 3.43 |
| EV/EBITDA | 16.51 |
| Quarterly Earnings Growth (YoY) | -0.60% |
| Quarterly Revenue Growth (YoY) | 8.70% |
| Shares Outstanding | $164.60M |
| Float | $156.25M |
| % Insiders | 1.09% |
| % Institutions | 103.60% |
Historical Volatility
HV 10-Day
28.66%
HV 20-Day
26.67%
HV 30-Day
25.64%
HV 60-Day
38.06%
HV Rank
29.0%
Volatility is currently expanding
Analyst Ratings
Consensus ($299.63 target)
3
Strong Buy16
Buy3
HoldLatest News
Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research10/8/2026Positive
IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today at TechIQ 2026 introduced IQVIA Life Science ModelsTM to help predict clinical trial outcomes. IQVIA Life Science Models are a suite of purpose-built models for life sciences, combining IQVIA's proprietary expert content, deep domain knowledge and established regulatory, com.
Business Wire10/7/2026Neutral
IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today at TechIQ 2026 introduced IQVIA Explorer™ to help customers make better-informed commercial decisions. IQVIA Explorer turns complex, one-time analytics projects into an always-on commercial intelligence capability. Users can apply external indicators and ask business questio.
Business Wire10/7/2026Neutral
Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity
IQV's vast healthcare database, AI-enabled capabilities and strong R&DS bookings support growth, while low liquidity and $14.1B net debt remain in focus.
Zacks Investment Research10/2/2026Positive
IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its third-quarter 2026 financial results before the market opens on Tuesday, October 27, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompanyin.
Business Wire9/29/2026Neutral
IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know
IQV's accelerating organic growth, robust R&DS bookings and expanding AI adoption are strengthening demand visibility and business momentum.
Zacks Investment Research9/16/2026Positive
Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research9/11/2026Positive
IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years faster. Traditional approaches in clinical development no longer keep pace with increasing trial complexity. IQVIA Predictive Clinical.
Business Wire9/3/2026Neutral
IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced it received recognition this year from multiple independent industry awards programs for its use of AI to help healthcare and life sciences organizations improve decisions, strengthen regulated workflows, protect patient privacy and optimize clinical trial executio.
Business Wire8/27/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IQV and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 10/17/2026